How has Biostem Technologies ROCE changed compared to the previous year?

Return on Capital Employed (ROCE) of Biostem Technologies changed from 790.79 % to 76.33 %, representing a -90.35% change. The value is lower than the previous year.

What is the Biostem Technologies ROCE?

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Biostem Technologies with sector peers and the industry average to assess whether it is attractive.

How does Biostem Technologies ROCE compare to the industry average?

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Biostem Technologies ROCE

BSEM

The Return on Capital Employed (ROCE) of Biostem Technologies (BSEM) as of Aug 1, 2026 is 76.33 %. In the previous year, Return on Capital Employed (ROCE) was 790.79 % — a change of -90.35% (lower).

Get this data via API

Financial Data API

ROCE

76.33 %

YoY

-90.35%

Last updated: Aug 1, 2026

In 2026, Biostem Technologies's return on capital employed (ROCE) was 76.33 %, a -90.35% increase from the 790.79 % ROCE in the previous year.

Access this data via the Eulerpool API

Docs Get Free API Key

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Biostem Technologies's Return on Capital Employed (ROCE)

Biostem Technologies's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Biostem Technologies's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Biostem Technologies's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Biostem Technologies’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Biostem Technologies ROCE

Biostem Technologies Stock analysis

ROCE Details

Unraveling Biostem Technologies's Return on Capital Employed (ROCE)

Year-to-Year Comparison

Impact on Investments

Interpreting ROCE Fluctuations

Frequently Asked Questions about Biostem Technologies stock

What is the Biostem Technologies ROCE 2026?

How has Biostem Technologies ROCE changed compared to the previous year?

How has Biostem Technologies ROCE developed historically?

What is the Biostem Technologies ROCE?

What is a good ROCE?

How does Biostem Technologies ROCE compare to the industry average?

Profitability — Biostem Technologies

All Key Metrics — Biostem Technologies

Valuation

Income Statement

Margins

Balance Sheet

Cash Flow

Profitability

Leverage

Growth

Dividend

Workforce

Quality

Other